Literature DB >> 7563456

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

C J Boushey1, S A Beresford, G S Omenn, A G Motulsky.   

Abstract

OBJECTIVES: To determine the risk of elevated total homocysteine (tHcy) levels for arteriosclerotic vascular disease, estimate the reduction of tHcy by folic acid, and calculate the potential reduction of coronary artery disease (CAD) mortality by increasing folic acid intake. DATA SOURCES: MEDLINE search for meta-analysis of 27 studies relating homocysteine to arteriosclerotic vascular disease and 11 studies of folic acid effects on tHcy levels. STUDY SELECTION AND DATA EXTRACTION: Studies dealing with CAD, cerebrovascular disease, and peripheral arterial vascular disease were selected. Three prospective and six population-based case-control studies were considered of high quality. Five cross-sectional and 13 other case-control studies were also included. Causality of tHcy's role in the pathogenesis of vascular disease was inferred because of consistency across studies by different investigators using different methods in different populations. DATA SYNTHESIS: Elevations in tHcy were considered an independent graded risk factor for arteriosclerotic vascular diseases. The odds ratio (OR) for CAD of a 5-mumol/L tHcy increment is 1.6 (95% confidence interval [CI], 1.4 to 1.7) for men and 1.8 (95% CI, 1.3 to 1.9) for women. A total of 10% of the population's CAD risk appears attributable to tHcy. The OR for cerebrovascular disease (5-mumol/L tHcy increment) is 1.5 (95% CI, 1.3 to 1.9). Peripheral arterial disease also showed a strong association. Increased folic acid intake (approximately 200 micrograms/d) reduces tHcy levels by approximately 4 mumol/L. Assuming that lower tHcy levels decrease CAD mortality, we calculated the effect of (1) increased dietary folate, (2) supplementation by tablets, and (3) grain fortification. Under different assumptions, 13,500 to 50,000 CAD deaths annually could be avoided; fortification of food had the largest impact.
CONCLUSIONS: A 5-mumol/L tHcy increment elevates CAD risk by as much as cholesterol increases of 0.5 mmol/L (20 mg/dL). Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease. Clinical trials are urgently needed. Concerns about masking cobalamin deficiency by folic acid could be lessened by adding 1 mg of cobalamin to folic acid supplements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7563456     DOI: 10.1001/jama.1995.03530130055028

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  462 in total

1.  Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications.

Authors:  N Mahmud; A Molloy; J McPartlin; R Corbally; A S Whitehead; J M Scott; D G Weir
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 3.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 4.  Homocysteine: a sulph'rous fire.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 5.  Evidence based cardiology: emerging approaches in preventing cardiovascular disease.

Authors:  E M Lonn; S Yusuf
Journal:  BMJ       Date:  1999-05-15

Review 6.  Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review.

Authors:  R Padwal; S E Straus; F A McAlister
Journal:  BMJ       Date:  2001-04-21

7.  Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis.

Authors:  P A Isotalo; J G Donnelly
Journal:  Mol Diagn       Date:  2000-03

8.  Determinants of homocysteine levels in Ivorian rural population.

Authors:  Georges Tiahou; Anne-Marie Dupuy; Isabelle Jaussent; Daniel Sees; Jean-Paul Cristol; Stephanie Badiou
Journal:  Int J Vitam Nutr Res       Date:  2009-09       Impact factor: 1.784

9.  Hyperhomocyst(e)inemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

10.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.